Highlights
- Sequential administration of radiotherapy (RT) and immunotherapy (iRT) is associated with significantly longer overall survival (OS) compared to concurrent administration in newly diagnosed advanced non-small cell lung cancer (NSCLC).
- The addition of chemotherapy as a systemic treatment partner continues to correlate with improved survival outcomes in the first-line iRT setting.
- In the refractory disease setting, maintenance of immune checkpoint inhibitors (ICI) following RT demonstrated a numerical, though not statistically significant, trend toward improved OS.
- These real-world findings from the OCEANUS study provide a critical framework for designing future prospective randomized controlled trials (RCTs).
Background
The therapeutic landscape for advanced non-small cell lung cancer (NSCLC) has been radically transformed by the introduction of immune checkpoint inhibitors (ICIs). However, despite their success, a significant proportion of patients do not achieve durable responses. Radiotherapy (RT), traditionally viewed as a local cytoreductive modality, is increasingly recognized for its immunomodulatory potential. By inducing immunogenic cell death, releasing tumor-associated antigens, and modulating the tumor microenvironment (TME), RT can act as an “in-situ vaccine” that potentially enhances the efficacy of ICIs—a phenomenon often discussed in the context of the abscopal effect.
While the synergy between RT and immunotherapy (iRT) is biologically plausible, the optimal clinical integration of these modalities remains controversial. Specifically, the sequencing of RT (concurrent vs. sequential) and the necessity of concomitant chemotherapy are major points of clinical debate. While the PACIFIC trial established the benefit of sequential ICI (durvalumab) after chemoradiotherapy in Stage III NSCLC, the evidence for Stage IV or refractory disease has been largely fragmented and lacking in randomized clarity. The OCEANUS study, a territory-wide cohort analysis, provides much-needed real-world evidence to address these sequencing and combinatorial questions.
Key Content
Sequential vs. Concurrent iRT in Newly Diagnosed Disease
The primary conflict in iRT sequencing revolves around the balance of immune activation versus immunosuppression. The OCEANUS study evaluated 155 patients with newly diagnosed advanced NSCLC who received iRT. The results demonstrated a significant survival advantage for the sequential approach. Patients receiving sequential iRT achieved a median real-world overall survival (rwOS) of 20.3 months, compared to 16.0 months in the concurrent group (adjusted hazard ratio [aHR], 0.68; 95% CI, 0.47-0.99; P = .045).
The biological rationale for sequential superiority may involve the temporal dynamics of the immune response. Concurrent radiotherapy, particularly when involving large fields, can be lymphodepleting, potentially destroying the very effector T-cells that ICIs aim to invigorate. Sequential administration may allow for a “priming” phase where RT creates a more inflammatory TME before ICI introduction, or conversely, allows the immune system to recover from radiation-induced lymphopenia before full-scale checkpoint blockade.
The Role of Chemotherapy as a Treatment Partner
Despite the rise of chemo-free regimens, the OCEANUS data reinforces the value of chemotherapy in the upfront management of advanced NSCLC. In newly diagnosed patients, the receipt of chemotherapy alongside iRT was associated with significantly longer survival. This suggests that the systemic control provided by cytotoxic agents remains vital for controlling micrometastatic disease and perhaps further enhancing tumor antigen release, complementing the local effects of RT and the systemic activation of ICIs.
Management of Refractory NSCLC and ICI Maintenance
In the refractory setting (n=180), the study assessed whether continuing ICI as maintenance after palliative or salvage RT improved outcomes. While the results did not reach statistical significance, a numerical trend favored ICI maintenance (median rwOS 11.2 months vs. 6.7 months; P = .20). Unlike the newly diagnosed cohort, the addition of chemotherapy in the refractory setting did not significantly alter OS, suggesting that in heavily pre-treated patients, the focus may shift more toward immune-modulatory strategies rather than further cytotoxic intensification.
Methodological Advances: The OCEANUS Study Design
The OCEANUS study utilized the Hong Kong Hospital Authority’s Clinical Data Analysis and Reporting System (CDARS), covering over 90% of the population. To mitigate the inherent biases of observational data, the researchers employed overlap weighting—a sophisticated propensity score-weighted method—ensuring that the comparison between treatment groups was robust and balanced across clinical variables. This level of real-world evidence provides high-quality data that bridges the gap between controlled clinical trials and everyday practice.
Expert Commentary
The findings of the OCEANUS study are hypothesis-generating and clinically provocative. The preference for sequential iRT in newly diagnosed patients suggests that the “more is better” approach (concurrent therapy) may not always hold true when dealing with the delicate kinetics of the immune system. Clinicians should consider that the timing of RT relative to ICI may be just as important as the dose or the target.
However, limitations must be acknowledged. As a retrospective cohort study, even with advanced weighting techniques, there remains the potential for unmeasured confounding factors, such as PD-L1 expression levels or the specific volume and site of RT, which were not fully delineated in the primary results. Furthermore, the definition of “sequential” can vary; the window between RT and ICI initiation may be critical and requires further optimization. The lack of statistical significance in the refractory group suggests that the benefit of post-RT ICI maintenance may be restricted to specific patient subsets, possibly those with higher tumor mutational burden or lower baseline inflammatory markers.
From a biological standpoint, these results support the theory that RT should be used to prime the immune system. If concurrent RT leads to excessive T-cell apoptosis, the synergistic potential is lost. The sequential benefit seen here aligns with emerging evidence that the immune-stimulatory effects of radiation peak days to weeks after the final fraction.
Conclusion
The OCEANUS study provides pivotal real-world evidence that in newly diagnosed advanced NSCLC, sequential radiotherapy and immunotherapy, complemented by chemotherapy, offers a superior survival benefit over concurrent administration. In the refractory setting, the role of ICI maintenance post-RT shows promise but requires more rigorous validation. As we move toward a more personalized approach to lung cancer treatment, these findings underscore the necessity of prospective randomized trials to establish the definitive “gold standard” for iRT sequencing. For now, the sequential approach stands as a robust strategy to maximize the synergistic potential of local and systemic therapies.
References
- Zhou H, Wang SC, Lee TTL, et al. Combination of Radiotherapy and Immunotherapy in Advanced Non-Small Cell Lung Cancer. JAMA oncology. 2026-03-26. PMID: 41885834.
- Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919-1929.
- Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019;5(9):1276-1282.